Every material Form 8-K Thermo Fisher Scientific filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Thermo Fisher Scientific announced on October 27, 2026 that Executive Vice President Michael D. Shafer will retire effective December 31, 2026. The filing does not give a reason for the retirement or name a successor, so its effect on shareholders is not stated.
Michael D. Shafer, Executive Vice President, will retire effective December 31, 2026.
The Company announced the retirement on October 27, 2026.
The filing does not name a successor or describe any compensation arrangements.
Thermo Fisher reported third-quarter 2026 results for the period ended September 26, 2026, with revenue up 9% to $12.14 billion and GAAP diluted EPS up 9% to $4.64. Organic revenue growth was 6%, and the company said it would give updated 2026 guidance on its earnings call that morning, so shareholders will get the outlook only through that call and not in this filing.
Revenue $12.14 billion, up from $11.12 billion a year earlier; organic growth 6%
Thermo Fisher reported second-quarter 2026 results for the quarter ended June 27, with revenue up 10% to $11.99 billion, including 5% organic growth. GAAP diluted EPS rose 9% to $4.68 and adjusted EPS rose 13% to $6.03. The company said it will provide updated 2026 guidance on its earnings call that morning, so the new outlook is not in the filing.
Q2 revenue was $11.99 billion versus $10.85 billion a year earlier; organic growth was 5%.
GAAP operating income was $2.09 billion, up 14%, with operating margin at 17.4% versus 16.9%.
The company repurchased $1.0 billion of stock during the quarter and announced the divestiture of its microbiology business.
Thermo Fisher reported first-quarter 2026 results for the quarter ended March 28, 2026, with revenue up 6% to $11.01 billion and GAAP diluted EPS up 11% to $4.43. Organic revenue growth was 1%, and the company said it completed the Clario acquisition and repurchased $3.0 billion of stock during the quarter. The company said it will provide updated 2026 guidance on its earnings call, so the filing itself contains no new guidance.
Revenue grew 6% to $11.01 billion from $10.36 billion a year earlier; organic revenue growth was 1%.
GAAP diluted EPS was $4.43, up 11%; adjusted EPS was $5.44, up 6%.
GAAP operating margin was 16.9%, compared with 16.6%; adjusted operating margin was 21.8%, compared with 21.9%.
Updated 2026 guidance will be given on the April 23, 2026 earnings call at 8:30 a.m. Eastern Time.
Thermo Fisher said it closed its acquisition of Clario Holdings, a provider of endpoint data solutions for clinical trials, for $8.875 billion in cash plus possible earn-out and other payments. The company expects the deal to contribute $0.45 of adjusted earnings per share in the first year after close, with details to come on its first-quarter earnings call.
Purchase price: $8.875 billion in cash at closing, plus $125 million due in January 2027 and up to $400 million in earn-out payments tied to 2026 and 2027 performance
Expected contribution: $0.45 adjusted EPS in the first year after close
Synergy target: approximately $175 million of adjusted operating income by year 5 after close
Clario will be part of the Laboratory Products and Biopharma Services segment
Thermo Fisher issued four series of senior notes in a public offering on February 12, 2026, totaling $3.8 billion in principal. The company expects net proceeds of about $3.76 billion and plans to use them to pay part of the cash consideration for its pending Clario Acquisition, which still requires customary closing conditions and regulatory approvals.
Four note series totaling $3.8 billion: $1.0 billion due 2031, $750 million due 2033, $1.3 billion due 2036 and $750 million due 2046
Expected net proceeds of approximately $3.76 billion after underwriting discounts and estimated offering expenses
Proceeds intended to pay a portion of the cash consideration for the previously announced Clario Acquisition, which is subject to closing conditions and regulatory approvals
Thermo Fisher reported fourth-quarter and full-year 2025 results on January 29, 2026. Revenue and earnings per share both grew from the prior-year periods, though the fourth-quarter adjusted operating margin slipped to 23.6% from 23.9%. The filing contains no 2026 guidance; the company said it will provide that on its earnings call that morning.
Fourth-quarter revenue was $12.21 billion, up 7% from $11.40 billion, with organic revenue growth of 3%.
Fourth-quarter GAAP diluted EPS was $5.21, up 9%; adjusted EPS was $6.57, up 8%.
Full-year 2025 revenue was $44.56 billion, up 4%; full-year GAAP diluted EPS was $17.74, up 7%.
2026 financial guidance will be given on the earnings conference call at 8:30 a.m. Eastern Time on January 29, 2026.
Thermo Fisher said Chief Operating Officer Michel Lagarde and Executive Vice President Frederick M. Lowery will leave the company to pursue other opportunities, with departures on March 31, 2026 and February 28, 2026. Effective March 1, 2026, Marc N. Casper becomes Chairman and Chief Executive Officer, and Gianluca Pettiti moves up to President and Chief Operating Officer, a leadership reshuffle that changes who runs the company day to day.
Michel Lagarde, EVP and COO since 2021, departs March 31, 2026
Frederick M. Lowery, EVP since 2024, departs February 28, 2026
Effective March 1, 2026: Marc N. Casper becomes Chairman and CEO
Gianluca Pettiti promoted to President and COO; Michael Shafer takes an expanded role reporting to the CEO
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Thermo Fisher Scientific filing is on SEC EDGAR ↗. 8-K briefs of other companies →